Nkarta, Inc. Employee-related Liabilities, Current
Nkarta, Inc. (NKTX) had Employee-related Liabilities, Current of $4.21 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:EmployeeRelatedLiabilitiesCurrent · last filed 2026-08-10
- 2026-06-30: Employee-related Liabilities, Current $4.21M.
- 2026-03-31: Employee-related Liabilities, Current $2.98M.
- 2025-12-31: Employee-related Liabilities, Current $6.07M.
- 2025-09-30: Employee-related Liabilities, Current $5.67M.
| Period end | Employee-related Liabilities, Current | Employee-related Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $4.21M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $2.98M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $6.07M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $5.67M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $5.03M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $6.12M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $7.92M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $7.01M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $4.92M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $3.77M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $6.72M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $6.02M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $4.93M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $3.77M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $6.69M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $5.59M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $3.74M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $2.65M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $5.45M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $4.50M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $3.42M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $2.09M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $3.53M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $2.54M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $1.75M 10-Q · filed 2020-08-20 | |
| 2019-12-31 | $1.68M 10-K · filed 2021-03-25 | $1.68M 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |